coumarin has been researched along with Disease Models, Animal in 26 studies
2H-chromen-2-one: coumarin derivative
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to explore the inhibition efficacy of new synthetic coumarinolignans (SCLs) against the secretion of pro-inflammatory cytokines in two in vivo models of inflammation." | 7.96 | New synthetic coumarinolignans as attenuators of pro-inflammatory cytokines in LPS-induced sepsis and carrageenan-induced paw oedema models. ( Araya, H; Begum Ahil, S; Fujimoto, Y; Hira, K; Kulkarni, OP; Kumar, SS, 2020) |
| " In the present study, we identified that nodakenin, a coumarin isolated from the roots of Angelicae gigas, functions effectively against unilateral ureteral obstruction (UUO)-induced fibrosis via down-regulating Snail1 expression." | 7.96 | Nodakenin alleviated obstructive nephropathy through blunting Snail1 induced fibrosis. ( Li, J; Tan, R; Wang, L; Zhao, S; Zhong, X, 2020) |
| " The efficacy of coumarin (1,2-benzopyrone) was examined for the regulation of hyperthyroidism in female rats." | 7.74 | Amelioration of L-thyroxine-induced hyperthyroidism by coumarin (1,2-benzopyrone) in female rats. ( Kar, A; Panda, S, 2007) |
| "Antiepileptic drugs are the mainstream treatment for epilepsy; however, the drug resistance occurring in 20-30% of patients and side effects of available medications have resulted in a search for natural remedies that can support disease therapy." | 6.61 | Coumarins as potential supportive medication for the treatment of epilepsy. ( Andres-Mach, M; Bryda, J; Szewczyk, A; Zagaja, M, 2019) |
| " In addition, 9d demonstrated decent bioavailability (F = 39." | 5.56 | Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis. ( Chen, L; Deng, D; Lan, T; Pei, H; Tang, M; Xue, L; Yang, Z; Ye, H; Zheng, S; Zhu, J, 2020) |
| "Hydrogen sulfide (H2S) is an important gaseous signaling agent mediated by many physiological processes and diseases." | 5.40 | Inorganic-organic hybrid nanoprobe for NIR-excited imaging of hydrogen sulfide in cell cultures and inflammation in a mouse model. ( Chen, W; Huang, L; Huang, W; Loo, JS; Pei, W; Wang, C; Yan, Q; Yao, C; Zhang, Q; Zhou, Y; Zhu, J, 2014) |
| "The aim of the study was to explore the inhibition efficacy of new synthetic coumarinolignans (SCLs) against the secretion of pro-inflammatory cytokines in two in vivo models of inflammation." | 3.96 | New synthetic coumarinolignans as attenuators of pro-inflammatory cytokines in LPS-induced sepsis and carrageenan-induced paw oedema models. ( Araya, H; Begum Ahil, S; Fujimoto, Y; Hira, K; Kulkarni, OP; Kumar, SS, 2020) |
| " In the present study, we identified that nodakenin, a coumarin isolated from the roots of Angelicae gigas, functions effectively against unilateral ureteral obstruction (UUO)-induced fibrosis via down-regulating Snail1 expression." | 3.96 | Nodakenin alleviated obstructive nephropathy through blunting Snail1 induced fibrosis. ( Li, J; Tan, R; Wang, L; Zhao, S; Zhong, X, 2020) |
| "Previous work established a coumarin scaffold as a starting point for inhibition of Mycobacterium tuberculosis (Mtb) FadD32 enzymatic activity." | 3.88 | Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors. ( Barros-Aguirre, D; Bates, RH; Fang, C; Fernandez-Menendez, R; Fisher, S; Gomez, JE; Guijarro-Lopez, L; Hubbard, BK; Hung, DT; Lee, KK; Lopez-Roman, EM; Nietupski, R; Peng, Z; Serrano-Wu, MH; Yin, Y, 2018) |
| " were screened with mice model of acute myocardial hypoxia induced by isoproterenol and pituitrin, eight compounds, i." | 3.77 | Anti-hypoxia activity and related components of Rhodobryum giganteum par. ( Cai, Y; Chen, R; Lu, X; Lu, Y; Wei, Q, 2011) |
| " The efficacy of coumarin (1,2-benzopyrone) was examined for the regulation of hyperthyroidism in female rats." | 3.74 | Amelioration of L-thyroxine-induced hyperthyroidism by coumarin (1,2-benzopyrone) in female rats. ( Kar, A; Panda, S, 2007) |
| "Antiepileptic drugs are the mainstream treatment for epilepsy; however, the drug resistance occurring in 20-30% of patients and side effects of available medications have resulted in a search for natural remedies that can support disease therapy." | 2.61 | Coumarins as potential supportive medication for the treatment of epilepsy. ( Andres-Mach, M; Bryda, J; Szewczyk, A; Zagaja, M, 2019) |
| " In addition, 9d demonstrated decent bioavailability (F = 39." | 1.56 | Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis. ( Chen, L; Deng, D; Lan, T; Pei, H; Tang, M; Xue, L; Yang, Z; Ye, H; Zheng, S; Zhu, J, 2020) |
| "Osthole is an active constituent isolated from the fruit of Cnidium monnieri (L." | 1.51 | The in vitro and in vivo anti-inflammatory effect of osthole, the major natural coumarin from Cnidium monnieri (L.) Cuss, via the blocking of the activation of the NF-κB and MAPK/p38 pathways. ( Chen, D; Fan, H; Gao, Z; Ji, K; Li, X; Liang, H; Liu, P; Liu, Y; Wang, X; Wu, J; Zhao, F, 2019) |
| "Hydrogen sulfide (H2S) is an important gaseous signaling agent mediated by many physiological processes and diseases." | 1.40 | Inorganic-organic hybrid nanoprobe for NIR-excited imaging of hydrogen sulfide in cell cultures and inflammation in a mouse model. ( Chen, W; Huang, L; Huang, W; Loo, JS; Pei, W; Wang, C; Yan, Q; Yao, C; Zhang, Q; Zhou, Y; Zhu, J, 2014) |
| "Coumarin was one of those tried as an anti-coagulant with a marginal efficacy." | 1.30 | Facilitation of retinal function recovery by coumarin derivatives. ( Chiou, GC; Kapingu, MC; Liu, SX; Wang, MS, 1997) |
| "Coumarin was also shown to possess antimetastatic activity in a Dunning R3327-MatLu tumour model." | 1.29 | Antitumour activity of coumarin in prostate and mammary cancer models. ( Kager, M; Maucher, A; von Angerer, E, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 7 (26.92) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Kim, H | 1 |
| Maeng, HJ | 1 |
| Kim, JH | 1 |
| Yoon, JH | 1 |
| Oh, Y | 1 |
| Paek, SM | 1 |
| Lee, Y | 1 |
| Olaya, MDP | 1 |
| Vergel, NE | 1 |
| López, JL | 1 |
| Viña, MD | 1 |
| Guerrero, MF | 1 |
| Deng, D | 1 |
| Pei, H | 1 |
| Lan, T | 1 |
| Zhu, J | 2 |
| Tang, M | 1 |
| Xue, L | 1 |
| Yang, Z | 2 |
| Zheng, S | 1 |
| Ye, H | 1 |
| Chen, L | 1 |
| Kumar, SS | 1 |
| Hira, K | 1 |
| Begum Ahil, S | 1 |
| Kulkarni, OP | 1 |
| Araya, H | 1 |
| Fujimoto, Y | 1 |
| Jiang, X | 1 |
| Guo, J | 1 |
| Lv, Y | 1 |
| Yao, C | 2 |
| Zhang, C | 2 |
| Mi, Z | 1 |
| Shi, Y | 1 |
| Gu, J | 1 |
| Zhou, T | 1 |
| Bai, R | 1 |
| Xie, Y | 1 |
| Li, J | 1 |
| Wang, L | 2 |
| Tan, R | 1 |
| Zhao, S | 1 |
| Zhong, X | 1 |
| Rath, B | 1 |
| Abul Qais, F | 1 |
| Patro, R | 1 |
| Mohapatra, S | 1 |
| Sharma, T | 1 |
| Fang, C | 1 |
| Lee, KK | 1 |
| Nietupski, R | 1 |
| Bates, RH | 1 |
| Fernandez-Menendez, R | 1 |
| Lopez-Roman, EM | 1 |
| Guijarro-Lopez, L | 1 |
| Yin, Y | 1 |
| Peng, Z | 1 |
| Gomez, JE | 1 |
| Fisher, S | 1 |
| Barros-Aguirre, D | 1 |
| Hubbard, BK | 1 |
| Serrano-Wu, MH | 1 |
| Hung, DT | 1 |
| Lingaraju, GS | 1 |
| Balaji, KS | 1 |
| Jayarama, S | 1 |
| Anil, SM | 1 |
| Kiran, KR | 1 |
| Sadashiva, MP | 1 |
| Fan, H | 1 |
| Gao, Z | 1 |
| Ji, K | 1 |
| Li, X | 2 |
| Wu, J | 1 |
| Liu, Y | 2 |
| Wang, X | 1 |
| Liang, H | 1 |
| Liu, P | 1 |
| Chen, D | 1 |
| Zhao, F | 1 |
| Riaz, MK | 1 |
| Zhang, X | 1 |
| Wong, KH | 1 |
| Chen, H | 1 |
| Liu, Q | 1 |
| Chen, X | 1 |
| Zhang, G | 1 |
| Lu, A | 1 |
| Bryda, J | 1 |
| Zagaja, M | 1 |
| Szewczyk, A | 1 |
| Andres-Mach, M | 1 |
| Wang, C | 2 |
| Wang, T | 1 |
| Zhou, N | 1 |
| Pan, XY | 1 |
| He, HZ | 1 |
| Nam, SO | 1 |
| Park, DH | 1 |
| Lee, YH | 1 |
| Ryu, JH | 1 |
| Lee, YS | 1 |
| Mohanraj, R | 1 |
| Sivasankar, S | 1 |
| Han, J | 1 |
| Sun, L | 1 |
| Huang, X | 1 |
| Li, Z | 1 |
| Qian, H | 1 |
| Huang, W | 2 |
| Zhou, Y | 1 |
| Chen, W | 1 |
| Pei, W | 1 |
| Huang, L | 1 |
| Yan, Q | 1 |
| Loo, JS | 1 |
| Zhang, Q | 1 |
| Cruzan, G | 1 |
| Bus, J | 1 |
| Banton, M | 1 |
| Gingell, R | 1 |
| Carlson, G | 1 |
| Alves, CF | 1 |
| Alves, VB | 1 |
| de Assis, IP | 1 |
| Clemente-Napimoga, JT | 1 |
| Uber-Bucek, E | 1 |
| Dal-Secco, D | 1 |
| Cunha, FQ | 1 |
| Rehder, VL | 2 |
| Napimoga, MH | 1 |
| Cai, Y | 1 |
| Lu, Y | 1 |
| Chen, R | 1 |
| Wei, Q | 1 |
| Lu, X | 1 |
| Bighetti, AE | 1 |
| Antônio, MA | 1 |
| Kohn, LK | 1 |
| Foglio, MA | 1 |
| Possenti, A | 1 |
| Vilela, L | 1 |
| Carvalho, JE | 1 |
| Panda, S | 1 |
| Kar, A | 1 |
| Kim, YS | 1 |
| Bahn, KN | 1 |
| Hah, CK | 1 |
| Gang, HI | 1 |
| Ha, YL | 1 |
| von Angerer, E | 1 |
| Kager, M | 1 |
| Maucher, A | 1 |
| Liu, SX | 1 |
| Kapingu, MC | 1 |
| Wang, MS | 1 |
| Chiou, GC | 1 |
3 reviews available for coumarin and Disease Models, Animal
| Article | Year |
|---|---|
Coumarins as potential supportive medication for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Brain; Coumarins; Disease Models, Animal; Epilepsy; Humans; Seizures | 2019 |
Sweet potato (Ipomoea batatas [L.] Lam)--a valuable medicinal food: a review.
Topics: Animals; Anthocyanins; Antineoplastic Agents; Antioxidants; Cardiovascular Agents; Coumarins; Diseas | 2014 |
Mouse specific lung tumors from CYP2F2-mediated cytotoxic metabolism: an endpoint/toxic response where data from multiple chemicals converge to support a mode of action.
Topics: Adenocarcinoma; Adenoma; Animals; Bronchioles; Carcinogens; Cell Proliferation; Coumarins; Cytochrom | 2009 |
23 other studies available for coumarin and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Coumarins; Disease Models, Animal; Dopaminergic Neurons; Mice; Parkinson D | 2022 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combina | 2019 |
Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
Topics: Animals; Bleomycin; Cell Movement; Cell Survival; Cells, Cultured; Coumarins; Disease Models, Animal | 2020 |
New synthetic coumarinolignans as attenuators of pro-inflammatory cytokines in LPS-induced sepsis and carrageenan-induced paw oedema models.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Coumarins; Cytokines; Disease Models, Animal; Edema; | 2020 |
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Behavior, Animal; Binding Sites; Ce | 2020 |
Nodakenin alleviated obstructive nephropathy through blunting Snail1 induced fibrosis.
Topics: Angelica; Animals; Anti-Inflammatory Agents; Coumarins; Disease Models, Animal; Fibrosis; Gene Expre | 2020 |
Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Coumarins; Disease Models, Animal; Do | 2021 |
Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Coumarins; Disease Models, Animal; Drug Evaluati | 2018 |
Synthesis of new coumarin tethered isoxazolines as potential anticancer agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; | 2018 |
The in vitro and in vivo anti-inflammatory effect of osthole, the major natural coumarin from Cnidium monnieri (L.) Cuss, via the blocking of the activation of the NF-κB and MAPK/p38 pathways.
Topics: Animals; Anti-Inflammatory Agents; Cnidium; Colitis, Ulcerative; Coumarins; Dinoprostone; Disease Mo | 2019 |
Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Coumarins; Disease Models, Animal | 2019 |
Design, synthesis and evaluation of 9-hydroxy-7H-furo[3,2-g]chromen-7-one derivatives as new potential vasodilatory agents.
Topics: Animals; Benzopyrans; Coumarins; Crystallography, X-Ray; Disease Models, Animal; Drug Design; Furoco | 2014 |
Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Animals; Cholinesterase Inhibitors; Coumarins; Disease Models, Animal; Enzyme | 2014 |
Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
Topics: Animals; Coumarins; Diabetes Mellitus, Type 2; Disease Models, Animal; Exenatide; Glucagon-Like Pept | 2014 |
Inorganic-organic hybrid nanoprobe for NIR-excited imaging of hydrogen sulfide in cell cultures and inflammation in a mouse model.
Topics: Animals; Carbocyanines; Coumarins; Disease Models, Animal; Fluorescent Dyes; HeLa Cells; Humans; Hyd | 2014 |
Anti-inflammatory activity and possible mechanism of extract from Mikania laevigata in carrageenan-induced peritonitis.
Topics: Animals; Anti-Inflammatory Agents; Brazil; Carrageenan; Cell Movement; Coumarins; Disease Models, An | 2009 |
Anti-hypoxia activity and related components of Rhodobryum giganteum par.
Topics: Animals; Bryophyta; Cinnamates; Coumarins; Disease Models, Animal; Hypoxia; Isoproterenol; Male; Mic | 2011 |
Antiulcerogenic activity of a crude hydroalcoholic extract and coumarin isolated from Mikania laevigata Schultz Bip.
Topics: Animals; Anti-Ulcer Agents; Anticoagulants; Coumarins; Disease Models, Animal; Dose-Response Relatio | 2005 |
Amelioration of L-thyroxine-induced hyperthyroidism by coumarin (1,2-benzopyrone) in female rats.
Topics: Animals; Antithyroid Agents; Body Weight; Catalase; Cholesterol; Coumarins; Disease Models, Animal; | 2007 |
Inhibition of 7,12-dimethylbenz[a]anthracene induced mouse skin carcinogenesis by Artemisia capillaris.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Artemisia; Camphanes; Camphor; C | 2008 |
Antitumour activity of coumarin in prostate and mammary cancer models.
Topics: Adenocarcinoma; Animals; Coumarins; Disease Models, Animal; Female; Lung Neoplasms; Male; Mammary Ne | 1994 |
Facilitation of retinal function recovery by coumarin derivatives.
Topics: Animals; Anticoagulants; Coumarins; Dark Adaptation; Disease Models, Animal; Drugs, Chinese Herbal; | 1997 |